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Background. A unit of the European Mobile Laboratory (EMLab) consortium was deployed to the Ebola virus disease (EVD)
treatment unit in Guéckédou, Guinea, from March 2014 through March 2015.
Methods. The unit diagnosed EVD and malaria, using the RealStar Filovirus Screen reverse transcription–polymerase chain
reaction (RT-PCR) kit and a malaria rapid diagnostic test, respectively.
Results. The cleaned EMLab database comprised 4719 samples from 2741 cases of suspected EVD from Guinea. EVD was di-
agnosed in 1231 of 2178 hospitalized patients (57%) and in 281 of 563 who died in the community (50%). Children aged <15 years
had the highest proportion of Ebola virus–malaria parasite coinfections. The case-fatality ratio was high in patients aged <5 years
(80%) and those aged >74 years (90%) and low in patients aged 10–19 years (40%). On admission, RT-PCR analysis of blood
specimens from patients who died in the hospital yielded a lower median cycle threshold (Ct) than analysis of blood specimens
from survivors (18.1 vs 23.2). Individuals who died in the community had a median Ct of 21.5 for throat swabs. Multivariate logistic
regression on 1047 data sets revealed that low Ct values, ages of <5 and ≥45 years, and, among children aged 5–14 years, malaria
parasite coinfection were independent determinants of a poor EVD outcome.
Conclusions. Virus load, age, and malaria parasite coinfection play a role in the outcome of EVD.
Keywords. Filovirus; Ebola virus disease; malaria; Guinea; epidemic; mobile laboratory.
Since its discovery in 1976, Ebola virus (EBOV) has caused sev-
eral outbreaks of Ebola virus disease (EVD) in sub-Saharan
Africa, with case-fatality ratios (CFRs) of up to 90% [1]. The
largest EVD outbreak in history occurred from 2014 to 2016
in West Africa and primarily affected the countries of Guinea,
Liberia, and Sierra Leone [2]. As of March 2016, 28 639 con-
ﬁrmed cases with 11 316 deaths had been reported by the
World Health Organization (WHO) [3]. Outbreak control
mainly relied on preventing transmission through isolation of
individuals with suspected EVD and patients with conﬁrmed
EVD, community engagement, contact tracing, and rapid labo-
ratory diagnostic tests [4]. On request of the WHO Global Out-
break Alert and Response Network (GOARN) and Emerging
Dangerous Pathogens Laboratory Network, a laboratory unit
of the European Mobile Laboratory (EMLab) consortium was
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rapidly deployed to the EVD treatment unit (ETU) in Guécké-
dou, Guinea, immediately after the causative agent of the out-
break had been identiﬁed [2, 5]. The laboratory unit departed
from Europe on 26 March 2014, and the ﬁrst patient samples
were tested on-site by EBOV reverse transcription–polymerase
chain reaction (RT-PCR) on 30 March 2014. It was operational
until March 2015, when it was relocated to the ETU in Coyah.
Here, we report the analysis of the laboratory data generated by
EMLab in Guéckédou from March 2014 through March 2015,
in conjunction with epidemiological data collected by theWHO
country ofﬁce in Guinea.
METHODS
Patients and Specimens
A blood specimen was collected from live patients with suspect-
ed EVD to establish the diagnosis. TheWHO case deﬁnition for
a suspected case was as follows: “any person, alive or dead, suf-
fering or having suffered from a sudden onset of high fever and
having had contact with: a suspected, probable or conﬁrmed
Ebola or Marburg case; a dead or sick animal (for Ebola); a
mine (for Marburg); OR any person with sudden onset of
high fever and at least three of the following symptoms: head-
aches, lethargy, anorexia/loss of appetite, aching muscles or
joints, stomach pain, difﬁculty swallowing, vomiting, difﬁculty
breathing, diarrhea, hiccups; OR any person with inexplicable
bleeding; OR any sudden, inexplicable death” [6p2]. The vast
majority of suspected EVD cases were managed at the ETUs
in Guéckédou and Macenta, both of which were operated by
Médecins Sans Frontières. A few samples originated from pa-
tients who were managed in other places in Guinea. The
EMLab unit also tested suspected EVD cases being managed
in Liberia and Sierra Leone. Laboratory-conﬁrmed EVD cases
were admitted at the ETU. Patients with suspected EVD were
retested 1–2 days later if the result of their ﬁrst test, performed
on a sample collected within the ﬁrst 3 days after onset of symp-
toms, was negative. During this time, they were kept in the area
of the ETU reserved for individuals with suspected EVD. An-
other blood sample was collected for analysis from patients
who were scheduled for discharge from the ETU. In rare
cases, specimens of other body ﬂuids, such as urine, were col-
lected from live patients with EVD and tested. No further sam-
ples were collected from patients who died of EVD in the ETU.
In addition, EMLab tested oral swab specimens from patients
who were found dead in their communities (hereafter, “com-
munity deaths”).
Diagnostic Assays
Viral RNAwas extracted from 50 µL of whole blood collected in
ethylenediaminetetraacetic acid (EDTA)–lined tubes (hereafter,
“EDTA–whole blood”) or 140 µL of cell-free ﬂuid (plasma,
urine, amniotic ﬂuid, or saliva), using the QIAamp Viral
RNA Mini Kit (Qiagen). Comparison in the ﬁeld of cycle
threshold (Ct) values, using RT-PCR analysis of 50 µL of
EDTA–whole blood or 140 µL of plasma, revealed equivalent
results (mean Ct difference [±SD] between whole blood and
plasma,−0.08 ± 2.46; n = 12). Material on dry swabs was re-
leased in 200 µL of water by agitation, of which 50 µL was pro-
cessed. Noninactivated specimens were manipulated in a glove
box. After addition of AVL buffer and incubation, the tubes
were decontaminated and moved out of the glove box for
RNA extraction. EBOV RNA was detected using the RealStar
Filovirus Screen RT-PCR Kit 1.0 (Altona Diagnostics) on a
SmartCycler (Cepheid) [7]. The internal control template of
the kit was added to the sample before RNA extraction, and
only results with a valid run control were communicated. Ct
values were reported to the clinicians as a quantitative measure
of viral load. EDTA–whole blood was evaluated for the presence
of Plasmodium falciparum, Plasmodium vivax, Plasmodium
malariae, and Plasmodium ovale antigens by using the Binax-
Now Malaria (Alere) rapid diagnostic test (RDT) in the glove
box according to the manufacturers instructions [8]. This test
has an analytical sensitivity of 99.5% for a parasitemia level of
>1000 parasites/µL blood for P. falciparum [8], the predominant
Plasmodium species in Guinea [9]. This threshold provides a
reasonable compromise between sensitivity and speciﬁcity in
detecting true severe malaria, rather than severe disease with in-
cidental parasitemia, in areas with moderate-to-high transmission
[10, 11].
Data Management and Statistical Analysis
Demographic data for patients were provided by Médecins Sans
Frontières, the Red Cross, the WHO, national authorities, con-
tact tracing teams, and other partners in ﬁeld on the laboratory
request forms accompanying the sample. Name, age, sex, resi-
dence, ETU patient identiﬁer, sample identiﬁer, sample type,
collection date, date of symptom onset, EBOV RT-PCR result
with corresponding Ct value, and malaria RDT results were
captured in the EMLab database (Excel, Microsoft) and report-
ed on a daily basis to the WHO and national authorities. The
operational EMLab sample database was the basis for further
analysis. To facilitate allocation of various samples to individual
patients, validate the demographic information, and document
outcome, the EMLab database was merged manually with the
Guinean EVD patient database maintained at the WHO coun-
try ofﬁce in Conakry. Patient name and sample identiﬁer re-
corded in both databases were used as primary identiﬁers for
merging; additional variables were used to verify the match. In-
consistencies between the 2 databases and between sample en-
tries for the same patient were resolved, and the data were
cleaned as much as possible, using Stata 14 (StataCorp). On
the basis of speciﬁc criteria, patients were classiﬁed into 3
main categories for analysis: (1) suspected cases of EVD not
conﬁrmed by PCR testing (noncases), (2) patients with PCR-
conﬁrmed EVD (EVD cases), and (3) community deaths. Data-
base entries for patients who could not be assigned to one
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of these categories because of missing or conﬂicting data
(n = 200 samples) and cases managed in Liberia and Sierra
Leone (n = 1083 samples lacking any epidemiological data)
were excluded from the analysis. The ﬁnal database comprised
2741 patients with 4719 samples collected between 17 March
2014 and 29 March 2015. In hospitalized patients, only samples
collected at admission were included in the analysis.
Statistical analysis was performed with Stata 14. Categorical
variables were described as percentages. The denominator var-
ied between variables because of missing data. Continuous var-
iables were described by medians and interquartile ranges
(IQRs). Associations of independent variables with the dichot-
omous outcome (survival or death) were displayed with crude
(unadjusted) odds ratios (ORs). Multivariate logistic regression
models were used to account for confounding factors. Categor-
ical variables were contrasted against a reference value (dummy
coding). In the ﬁnal model, an interaction term (the product of
2 interacting categorical variables) was included to assess out-
come associations of one independent variable within levels
of another independent variable. To describe the interaction
effect, ORs were calculated for each level of the second indepen-
dent variable. The corresponding effect estimates of the interac-
tion term, used to derive the ORs, are provided as well.
Ethics
The National Committee of Ethics in Medical Research of
Guinea and the Ethics Committee of the Medical Association
of Hamburg approved the use of diagnostic leftover samples
and corresponding patient data for this study (permits 11/
CNERS/14 and PV4910).
RESULTS
The cleaned EMLab database contained 2178 cases of suspected
EVD (79%) who attended a hospital/ETU and 563 community
deaths (21%). EVD was conﬁrmed by PCR in 1231 suspected
cases (57%) and 281 community deaths (50%). The CFR of
hospitalized cases with conﬁrmed EVD was 60%. Demographic
and laboratory data are summarized in Table 1. Most patients
originated from the regions of N’Zérékoré (1955 [77%]), Kan-
kan (374 [15%]), and Faranah (196 [8%]).
The weekly incidence of EBOV RT-PCR–positive cases in the
hospital and community shows that the outbreak in Guéckédou
progressed in 2 major waves (March–July and August–January;
Figure 1A). However, speciﬁcally the community data suggest
that the 2 major waves actually consisted of 5 subwaves:
March–April, May–July, August–September, October–November,
and December–January. The median of the weekly EVD conﬁr-
mation rate among hospital attendees was 52% (IQR, 31%–
66%). The median weekly CFR for conﬁrmed cases of EVD
was 66% (IQR, 54%–79%), with a decreasing trend during the
outbreak period (Figure 1A). Among community deaths, the
median weekly EVD conﬁrmation rate was 50% (IQR, 13%–
71%). The median Ct for patients with EVD on admission to
the hospital showed no trend over time (Figure 1B). The coinfec-
tion rate with malaria parasites among hospitalized patients with
EVD also remained at a similar level during the epidemic, with
the notable exception of a drop in January 2015 (Figure 1B).
Figure 2 shows the age distributions among hospitalized pa-
tients with EVD and community deaths. Essentially, both dis-
tributions show 3 peaks—young children, young adults aged
15–50 years, and elderly persons—although this structure was
more pronounced among community deaths. EVD conﬁrma-
tion rates in the hospital were comparable among age groups,
with a median of 58% (IQR, 54%–62%). In the communities,
the EVD conﬁrmation rate varied more among the age groups
(median, 50%; IQR, 38%–59%) but had an overall decreasing
trend toward higher age.
A malaria RDT was performed for 1937 hospital attendees
(89%), of whom 541 (28%) tested positive. Malaria RDT–
positive patients had a median age of 20 years (IQR, 7–35
years) and thus were younger than malaria RDT–negative
Table 1. Characteristics of Individuals Included in the Analysis
Characteristic
EVD Suspected Cases in Hospital Community Deaths
Overall EBOV RT-PCR Positive EBOV RT-PCR Negative Overall EBOV RT-PCR Positive EBOV RT-PCR Negative
Individuals 2178/2178 (100) 1231/2178 (57) 947/2178 (43) 563 281/563 (50) 282/563 (50)
Female sex 1135/2157 (53) 645/1228 (53) 490/929 (53) 260/545 (48) 136/271 (50) 124/274 (45)
Age, y, median (IQR) 30 (18–44)a 30 (19–45)b 30 (18–42)c 37 (25–55)d 35 (23–53)e 40 (25–56)f
Malaria RDT positive 541/1937 (28) 261/1091 (24) 280/846 (33) Not tested Not tested Not tested
Fatal outcome 769/2049 (38) 719/1205 (60) 50/844 (6) 563 (100) 281 (100) 282 (100)
Data are proportion of individuals with the characteristic/no. evaluated (%), unless otherwise indicated.
Abbreviations: EBOV, Ebola virus; EVD, Ebola virus disease; IQR, interquartile range; RDT, rapid diagnostic test; RT-PCR, reverse transcription–polymerase chain reaction.
a Data are for 2153 observations.
b Data are for 1225 observations.
c Data are for 928 observations.
d Data are for 521 observations.
e Data are for 252 observations.
f Data are for 269 observations.
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patients (median age, 33 years; IQR, 24–45 years). The highest
malaria prevalence was observed among children aged <15
years, of whom 220 (59%) had a positive test result. The propor-
tion of malaria RDT–positive patients decreased relative to that
of EVD-positive patients toward the higher age groups
(Figure 3A). In total, 261 (24%) EVD cases had a malaria par-
asite coinfection. The highest proportion of coinfections was
found in children aged <15 years. The CFR for EVD showed
an age-related effect with 2 maxima and a minimum (Fig-
ure 3A). Maximum CFRs were observed in young children
aged <5 years (80% [63]) and elderly patients aged >74 years
(90% [18]). The lowest CFR was observed in 15–19-year-old
young adults (39% [39]). Malaria parasite coinfection increased
the CFR in 5–14-year-old children by >20% (Figure 3B).
Figure 4 shows the distributions of Ct values for the ﬁrst
blood sample collected from hospitalized patients who died of
or survived EVD and for the throat swab collected from com-
munity deaths. Patients who died in the hospital had a lower
median Ct on admission, indicating a higher virus load, than
survivors (18.1 vs 23.2). The median Ct for community deaths
(21.5) was 3.4 Ct units higher than for patients who died while
hospitalized, which may be related to the different clinical ma-
terial tested. Given the difference in Ct between people who sur-
vived and those who died of EVD, we have plotted the CFR
versus Ct categories to evaluate the relationship between virus
Figure 1. Frequency of patients tested by Ebola virus (EBOV) reverse transcrip-
tion–polymerase chain reaction (RT-PCR), case-fatality ratios (CFRs), cycle threshold
(Ct) values, and malaria parasite coinfection rate over time. A, EBOV RT-PCR results
are shown for 2178 patients attending an Ebola virus disease (EVD) treatment unit
(ETU; upper panel) and 563 patients who died in their communities (lower panel),
by week of the deployment period. For patients with EVD who were treated at an
ETU, the CFR is shown in the upper panel. B, Ct values on admission and malaria
parasite coinfection rate for patients with EVD who were treated at an ETU.
Abbreviation: RDT, rapid diagnostic test.
Figure 2. Age distribution for patients tested by Ebola virus (EBOV) reverse tran-
scription–polymerase chain reaction (RT-PCR). Results are shown for 2153 patients
attending an Ebola virus disease (EVD) treatment unit (A) and 521 patients who died
in their communities (B), by age category.
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load and outcome in more detail (Figure 5). The data show a
clear inverse correlation between Ct and CFR, indicating that
the Ct on admission has a strong prognostic value.
The analysis of individual factors indicated that age, malaria
parasite coinfection, and virus load may be outcome determi-
nants. Therefore, we assessed their inﬂuence, using logistic re-
gression models. Variables were Ct of the ﬁrst EBOV-positive
blood sample, age category (ie, 0–4, 5–14, 15–45, and >45
years), and malaria RDT result, stratiﬁed within the established
age groups. Complete data sets for 1047 EVD patients were
available for analysis. In the crude analysis, patients with
EVD who had lower Ct values on admission and an age of
≤4 years or ≥45 years had a higher chance of death (Table 2).
Malaria had no effect on outcome in the crude analysis. How-
ever, as 5–14-year-old children had the highest malaria parasite
coinfection rate and an increased CFR if coinfected with malar-
ia parasites (Figure 3B), we assumed an effect of malaria on out-
come in this speciﬁc age group, which is obliterated in the crude
Figure 3. Proportion of patients with Ebola virus disease (EVD) and/or malaria, as
well as case-fatality ratios (CFRs) for EVD, according to age and malaria parasite
coinfection status. A, The relative frequencies of hospitalized patients with positive
results of Ebola virus (EBOV) reverse transcription–polymerase chain reaction (RT-
PCR) analysis and/or malaria rapid diagnostic tests (RDTs) are shown. The CFR refers
to EVD cases irrespective of malaria parasite coinfection. B, CFR depending on age
group and malaria parasite coinfection status. The number of fatalities and total
number of patients per age group are shown below the graph. The data set used
to generate the graph (for 1047 patients) corresponds to the data set used to calcu-
late the regression models in Tables 2 and 3.
Figure 4. Distribution of cycle threshold (Ct) values on admission to hospital for
patients who died of or survived Ebola virus disease (EVD) and for individuals who
died of EVD in the community. Arrows and horizontal bars above the histograms in-
dicate medians and interquartile ranges (IQRs), respectively.
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analysis. Therefore, an interaction term (the combination of age
category and malaria RDT positivity) was included in the full
regression to model an interaction of age and malaria. In agree-
ment with the crude analysis, the full model revealed a higher
chance of fatal outcome in particular within the age categories
≤4 years and ≥45 years, irrespective of malaria parasite coinfec-
tion (Table 3). Consistent with the data shown in Figure 3B, an
effect of malaria RDT positivity was only seen in children 5–14
years of age, who had a higher chance of dying if coinfected with
malaria parasites. There was no evidence of an impact of
malaria parasite coinfection on outcome in the other age
groups. The Ct was not confounded by these variables and
showed a similar effect estimate as in the crude analysis.
DISCUSSION
During the stay in Guéckédou, EMLab tested specimens from
2741 patients with suspected EVD from Guinea who either at-
tended a hospital or died in their community. EVD was con-
ﬁrmed in 1512 cases, representing 44% of all EVD cases
reported from the entire country during that period [12]. Irre-
spective of whether patients attended a hospital or died in the
community, EVD was diagnosed in about 50% of all suspected
cases. This high incidence suggests that EVD was a major cause
of mortality and morbidity in the affected area during the epi-
demic. Nearly 20% of all EVD cases died in the community and
were diagnosed on the basis of analysis of swabs. The median Ct
for swabs was 3.4 Ct units higher than the admission Ct for
blood from fatal hospital cases, which roughly corresponds to
a 1 log unit difference in virus load. Nevertheless, the Ct distri-
bution curve for swabs lies well within the detection range of the
EBOV RT-PCR assay. As the Ct values appear to be largely nor-
mally distributed, the observed curve suggests that the vast ma-
jority of throat swabs contain a virus load that can easily be
detected in that assay. Thus, a throat swab is a suitable clinical
specimen for postmortem EVD diagnostic testing. In addition,
the epidemic curve for EVD community deaths corresponds
quite well to the epidemic curve for people hospitalized with
EVD. Both imply that testing of community deaths is a reliable
and sensitive method for surveillance. Indeed, it has been suc-
cessfully used in the affected countries in the postoutbreak phase.
The CFR remained largely constant or slightly decreased dur-
ing the epidemic, until December 2014, when it dropped con-
siderable. The reason for this drop is not clear but may be
related to the higher median Ct value (23) and lower malaria
parasite coinfection rate (3%), compared with previous months,
and to the initiation of the JIKI trial in Guéckédou during this
period, which showed a trend toward efﬁcacy of favipiravir in
patients with a Ct of ≥20 [13]. The EMLab data have not
been collected for scientiﬁc purposes, and therefore our results
should be interpreted with caution. Patients attending the treat-
ment centers are not a random sample from the hospital’s catch-
ment area. Attendance at the ETU may be inﬂuenced by
campaigns, reputation of the center, perceived individual disease
severity, willingness to be tested, distance to the center, or avail-
ability of alternative treatment options. All of these factors may
change and explain the variation in CFR over time [14].
Virus load—in the ﬁeld, usually represented by the Ct—is
closely correlated with outcome, as has been observed in
previous outbreaks [15] as well as in the West African outbreak
[14, 16–24]. We found a difference between the median Ct val-
ues of EVD fatalities and survivors of 5.1 Ct units, roughly cor-
responding to a difference in virus RNA concentration of 1.5 log
Figure 5. Case-fatality ratios (CFRs) among hospitalized patients with Ebola virus
disease (EVD), according to cycle threshold (Ct) category. The Ct values for the first
Ebola virus reverse transcription–polymerase chain reaction–positive blood sample
from 2527 patients were included in the analysis.
Table 2. Crude (Unadjusted) Logistic Regression Analysis of the
Association Between a Fatal Outcome and Both Age and Malaria Rapid
Diagnostic Test (RDT) Result Among 1047 Patients With Ebola Virus
Disease
Variable
Fatal Cases/Total
Cases (%)
Crude Model, OR
for Fatal Outcome
(95% CI) P Value
Ct of EBOV RT-PCR
(increasing,
continuous)
602/1047 (57.5) 0.7 (.7–.7) <.001
Age category, y
0–4 42/55 (76.4) 2.9 (1.4–5.9) .004
5–14 65/123 (52.8) 1 (Reference)
15–44 322/603 (53.4) 1.0 (.7–1.5) .91
≥45 173/266 (65.0) 1.6 (1.1–2.6) .02
Malaria RDT result
Negative 452/798 (56.6) 1 (Reference)
Positive 150/249 (60.2) 1.2 (.9–1.5) .32
Abbreviations: CI, confidence interval; Ct, cycle threshold; EBOV, Ebola virus; OR, odds ratio;
RT-PCR, reverse transcription–polymerase chain reaction.
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units. Moreover, the Ct on admission has strong prognostic
value, providing a quantitative estimate of outcome. Patients
with EVD who have a Ct of <17 have a CFR of 95%, and those
with a Ct of >26 have a CFR of 15%. Between these 2 extremes,
the Ct is nearly perfectly (negatively) correlated with the CFR.
Malaria parasite coinfections occur in a signiﬁcant fraction of
patients with EVD and seem to codetermine the outcome. The
overall prevalence of coinfection was comparable to ﬁndings in
studies from Liberia [25]. As expected, we found the highest in-
cidence of malaria in children <15 years of age. Consistent with
this ﬁnding, the coinfection rate of Ebola virus and malaria
parasites was highest in this age group. However, the interaction
between malaria and EVD and their effect on outcome seems to
be complex. The CFR has a ﬁrst maximum in children aged
<5 years, followed by a minimum among individuals aged
10–19 years and a second maximum among patients
aged >74 years. Similar distributions have been observed in
other studies from the West African outbreak [20, 23, 26]. It
may be that both an immature immune system in conjunction
with malaria parasite coinfection leads to the increased CFR in
young children, while the high CFR in elderly individuals may
be due to comorbidities and a generally reduced health and im-
mune status. The shape of the EVD CFR curve by age resembles
the “U” or “W” shape of the mortality and CFR curves for severe
inﬂuenza [27], suggesting that similar host determinants might
underlie both distributions. The uneven malaria distribution
among the patients with EVD and the age dependency of the
effect of malaria parasite coinfection has been taken into account
by our full regression model. It revealed that both young age
(≤4 years) and malaria parasite coinfection in children aged
5–14 years are independent risk factors for a fatal outcome. The
lack of signiﬁcant contribution of malaria parasite coinfection in
most age groups may be the result of treatment with antimalarials
in the ETU (irrespective of age, all patients received artemisinin-
based combination therapy). In addition, the regression analysis
conﬁrmed the clear association between Ct and outcome.
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